← All trials
NCT04903899
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 19, 2021
- Primary completion
- May 20, 2026
- Completion date
- May 20, 2031
- First posted
- May 27, 2021
- Last posted
- May 27, 2021
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Karolinska InstituteLead sponsor
- Advanced Accelerator ApplicationsCollaborator
- Karolinska InstituteSponsor investigator
- Karolinska InstituteStudy chair
- NovartisCollaborator
- Karolinska InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.